BioTheranostics this week announced the appointment of Michael Dugan as its new chief medical officer and Catherine Schnabel as its VP of medical, clinical, and regulatory affairs.
Dugan was previously VP and chief medical officer at Roche Molecular Systems. Schnabel joined BioTheranostics in 2009. Previously she handled medical affairs at Amylin Pharmaceuticals and held research roles at Genoptix and Genentech.